Effect of Rabeprazole on Pachydermia Laryngis in Patients with Laryngopharyngeal Reflux
Article Sidebar
Main Article Content
Abstract
Introduction
Laryngopharyngeal reflux (LPR) is defined as the retrograde flow of gastric content into larynx and pharynx. It is a multifactorial syndrome. Empiric trial of PPI therapy represents the first step to confirm LPR and to treat it accordingly as all currently available diagnostic tests have poor sensitivity and specificity. However, there is no accepted protocol for the most effective treatment of patients with LPR. Objective of the study was to assess the effect of Rabeprazole on pachydermia laryngis (posterior commissure hypertrophy) in patients with LPR.
Materials and Methods
In this prospective study, 75 subjects diagnosed with LPR using Reflux symptom index (RSI) and Reflux finding score (RFS) tools were recruited. Using RFS, posterior commissure hypertrophy was scored at presentation and after 8 weeks of rabeprazole therapy. The mean pre- and post-treatment posterior commissure hypertrophy scores for each patient were compared using paired T-test.
Results
Posterior commissure hypertrophy did not show statistically significant improvement following 8 weeks of 20 mg once daily oral rabeprazole therapy.
Conclusion
Eight weeks of oral therapy with Rabeprazole 20 mg once daily did not show statistically significant improvement in posterior commissure hypertrophy.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: Position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otorhinolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002; 127(1):32-5
Delahunty JE. Acid laryngitis. J Laryngol Otol. 1972; 86:335–42
Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score. Laryngoscope 2001; 111(8):1313-7
Datta R, Datta K, Venkatesh MD. Laryngopharyngeal reflux: Larynx on fire. Medical Journal Armed Forces India 2010; 66:245-8
Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007; 3(3):363-79
Kambic V, Radsel Z. Acid posterior laryngitis. Aetiology, histology, diagnosis, and treatment. J Laryngol Otol 1984; 98:1237-40
Hill RK, Simpson CB, Velazquez R, Larson N. Pachydermia is not diagnostic of active laryngopharyngeal reflux disease. Laryngoscope 2004; 114(9):1557-61
Noordzij J, Khidr A, Evans B, Desper E, Mittal R, Reibel J, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope 2001; 111:2147-51
Reichel O, Dressel H, Wiederanders K, Issing W. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg 2008; 139:414-20
Lam P, Ng M, Cheung T, Wong B, Tan V, Fong D, et al. Rabeprazole is effective in treating laryngopharyngeal reflux in a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 2010; 8:770-6.